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Summary 
 
Hepatocellular carcinoma (HCC) is the 6th most common cause of cancer worldwide and contributes              
to 9% of the global mortality burden attributed to cancer. The limited options of classic systemic                
cancer therapies, the strict criteria for surgical resection and the global shortage of donor organs for                
transplantation have led to a search for alternative treatment modalities. Local image-guided,            
minimally invasive therapies have successfully filled the gap as therapeutic options for HCC,             
establishing themselves in practice guidelines across the world. Image-guided, minimally invasive           
therapies encompass local ablative modalities including Radiofrequency ablation (RFA), Cryotherapy,          
Microwave ablation (MWA), Laser ablation (LA) and High-intensity focused Ultrasound (HIFU) as            
well as intra-arterial treatment modalities such as transarterial chemoembolization (TACE),          
transarterial bland embolization (TAE) and transarterial radioembolization (TARE). Both ablative and           
transarterial therapies have revolutionized the management of HCC. This review article highlights            
some of the technical aspects of these therapies and provides up to date scientific evidence for their                 
clinical use. 
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Sažetak 
 
Hepatocelularni karcinom (HCC) je 6. po redu najčešći uzrok raka u svijetu i doprinosi do 9%                
globalnog tereta smrtnosti koja se pripisuje raku. Ograničene opcije klasičnih sistemskih terapija            
protiv raka, strogi kriteriji kirurških resekcija i globalni nedostatak donora organa za transplantaciju su              
doveli do potrage za alternativnim načinima liječenja. Lokalne minimalno invazivne terapije           
navođene slikom su uspješno ispunile prazninu u opcijama liječenja HCC, uspostavivši se u             
smjernicama za liječenje diljem svijeta. Minimalno invazivne terapije navođene slikom obuhvaćaju           
lokalne modalitete ablacije uključujući radiofrekventnu ablaciju (RFA), krioterapiju, mikrovalnu         
ablaciju (MWA), ablaciju laserom (LA) i ultrazvuk visokog intenziteta (HIFU) uz, također,            
intra-arterijske metode liječenja kao što su transarterijska kemoembolizacija (TACE), transarterijska          
bland embolizacija (TAE) i transarterijska radioembolizacija (TARE). Ablacijsko i transarterijsko          
liječenje su oba revolucionarizirali vođenje HCC. Ovaj pregledni članak naglašava neke od tehničkih             
aspetaka tih terapija i pruža najnovije znanstvene dokaze za njihovo kliničko korištenje.  
 
 
 
 
 
 1. Introduction 
 
With increasing incidence in many parts of the world, liver cancer continues to be a major contributor                 
to the global burden of disease in the 21st century.  
Liver cancer makes up 6% of the global cancer incidence and 9% of the global mortality burden                 
attributed to cancer. According to the WHO World Cancer Report, with an estimated 746,000 deaths               
in 2012, liver cancer ​is ​the second most common cause of cancer-related death, overshadowed only by                
lung cancer ​(1)​.  
Hepatocellular carcinoma (HCC) is by far the most common primary liver cancer, encompassing 80%              
of all primary liver cancers and representing the 6th most common cancer worldwide, with an               
estimated 554,000 and 228,000 new cases in 2012 in men and women, respectively.  
To this day, major risk factors for the development of HCC are chronic Hepatitis B and C infection as                   
well as chronic fatty liver disease associated with long-term alcohol consumption. Additionally,            
non-alcoholic fatty liver disease associated with metabolic syndrome has come into focus in relation              
to its synergistic contribution to the development of HCC ​(2)​.  
Despite the fact that the lowest rates are documented in North and South America and Northern                
Europe (10 in 100,000), an increase in HCV incidence has resulted in an increase in HCC in these                  
regions. Furthermore, the increasingly apparent importance of metabolic syndrome and the           
increasingly significant rates of obesity and diabetes may contribute to this trend. 
Conversely, countries in South-east Asia, a region with some of the highest rates of HCC (20 in                 
100,000), have seen a decline in incidence. Contributors to this decline are an overall decrease in                
aflatoxin exposure, a major synergist in HBV infection, as well as successful vaccination and              
treatment attempts for HBV ​(3)​. A 2009 cohort study published in Taiwan reported a significantly               
lower incidence of HCC when comparing vaccinated and unvaccinated children ​(4)​.  
 
The staging of cancer is necessary, as it serves a multitude of variables and goals, from accurately                 
estimating prognosis and survival rate to recommending appropriate primary and adjuvant           
intervention. HCC is of particular interest with regard to tumor staging, as it not only emcompasses                
the malignant potential of the tumor and its extension, but also the presence of underlying cirrhosis,                
which is predictive of treatment efficacy and applicability. Currently there are eight different staging              
systems used to depict the state of the primary tumor and predict the outcome of intervention, none of                  
which currently have universal acceptance. 
Conventional systems, like the TNM staging that primarily focuses on variables related to tumor              
characteristics, have shown to be of poor predictive value in HCC patients undergoing surgical              
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 treatment, in part because they do not take underlying hepatic function into account. In response,               
adjustments to the system have been made by proposing the introduction of a fourth stage, which                
indicates presence or absence of fibrosis. The TNM staging has since been endorsed by the American                
Joint Committee on Cancer (AJCC). Staging systems and scores like the Okuda staging system, the               
Chinese University Prognostic Index (CUPI) score, and the French classification have all been called              
into question due to the fact that all three lack a level of discrimination for early stages of HCC and                    
therefore are of limited prognostic value for pre-advanced stage cancers. The Cancer of the Liver               
Italian Program (CLIP) Score has proven to be of a higher discriminatory ​value​, but is limited in that                  
it does not recommend appropriate therapy based on its scoring ​(5)​.  
The Barcelona-Clinic Liver Cancer (BCLC) classification, officially endorsed by the European           
Association for the Study of the Liver and the European Organisation for Research and Treatment of                
Cancer (EASL–EORTC), accounts for variables regarding tumor status (size, number, invasion, N1,            
M1), liver function status (Child-Pugh’s) and health status (ECOG) ​(6)​. By classifying HCC patients              
into five stages (0, A, B, C, D) it further allocates recommended treatment options to each stage.                 
Research has shown BCLC to be superior in differentiating early-stage HCCs while recommending             
appropriate interventions including resection, orthotopic liver transplantation (OLT), and local          
ablation. Additionally, its variables include presence or absence of portal vein thrombosis (PVT),             
which, according to research, has shown decreased survival probability independently of other            
prognostic factors as it suggests vascular invasion. Lastly, particularly with regards to early-stage             
HCC, BCLC serves as a more detailed predictor of survival when compared to scoring systems such                
as CLIP or the Okuda staging system ​(7)​. 
 
One of the prerequisites for a precise staging system for HCC, aside from the multiplicity of                
influencing factors such as cirrhosis or portal vein hypertension, is the lack of successful systemic               
chemotherapy or hormone therapy. No systemic therapy has thus far proven effective in             
demonstrating improved survival in HCC, with the exception of Sorafenib, an oral multi-tyrosine             
kinase inhibitor. Clinical trials have proven Sorafenib to increase overall survival (OS) rate by nearly               
three months in patients with advanced HCC. However, given the fact that patients have largely been                
chosen with well-preserved liver function (Child-Pugh class A), it is to be expected that in patients                
with more advanced liver failure (Child-Pugh class B, C) results would be significantly poorer ​(8)​.               
Therefore, Sorafenib is accepted as standard systemic therapy for advanced HCC (BCLC C), only in               
cases of Child-Pugh class A ​(6)​. Other attempts of systemic treatment for HCC with Brivanib or                
Everolimus have demonstrated no improvement over Sorafenib ​(9,10)​. 
According to the clinical practice guidelines published by the EASL-EORTC, the main treatment of              
choice for solitary tumors with well-preserved liver function remains hepatic resection, which has an              
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 estimated 5-year survival rate of 60-80%. Following the BCLC classification, the main indicators for              
surgical resection are single <2 cm HCC or carcinoma in situ (BCLC stage 0), with additional                
considerations in patients with multifocal tumors meeting the Milan criteria (≤3 nodules ≤3 cm) who               
are not suited for liver transplantation ​(6)​. Research has shown 5-year survival drops significantly              
with increased size of the primary tumor (66%, 52% and 37% for tumors ≤2 cm, 2-5 cm and >5cm,                   
respectively) ​(11)​. Furthermore, multiple tumor resection has, until now, carried a considerably lower             
5-year survival rate compared to single-tumor resection. However, newer research shows comparable            
survival rates in patients with multiple tumors and preserved liver function undergoing surgical             
resection, indicating that the main reason for contraindication to resection in these cases is higher               
recurrence rates (exceeding 70% at 5 years) ​(12)​. The assessment of liver functional reserve has of                
late shifted from the rather crude Child-Pugh classification to more detailed and refined procedures              
involving indocyanine green retention rate at 15 min or hepatic venous pressure gradient (HVPG)              
(13)​. Platelet count, however, remains the most accessible parameter when assessing HVPG. In             
reality, using proper selection criteria of patients with HVPG <10 mmHg or platelet count of               
<100,000/mm³ yields an overall rate of fewer than 10% of HCC patients eligible for resection.  
Recommendations have been set to perform anatomical resections according to Couinaud with tumor             
margins of 2cm as this method has proven to yield better survival compared to narrow-margin               
resections of <1 cm. Narrow-margin resections should only be considered if a wide-margin resection              
is not advisable, either due to anatomic location or the severity of underlying cirrhosis ​(14)​.  
As one of the major challenges in surgical resection remains the high incidence of tumor recurrence,                
attempts have been made to use Interferon as adjuvant therapy. However, research has not shown               
universally successful adjuvant therapy for HCC undergoing resection, with the exception of            
subgroups in which late-recurrences could be significantly reduced ​(15)​. 
Following the BCLC guidelines, the second type of surgical intervention for HCC is liver              
transplantation. In line with the Milan Criteria, first introduced in 1996 by Mazzaferro et al., liver                
transplantation is indicated for either ≤3 nodules ≤3 cm, or single tumors ≤5 cm with advanced liver                 
dysfunction ​(16)​. Still in use today, the Milan Criteria is recognised as a separate prognostic category,                
demonstrating favourable outcome after liver transplantation, resulting in a 5-year survival rate of             
70% ​(17)​. However, the use of neoadjuvant therapy in liver transplantation has been the cause of                
further debate. With the current shortage of donors and consequent longer waiting time, an estimated               
20% of HCC patients will drop out of the waiting list before receiving a liver transplant ​(6,18)​. The                  
strategy behind the introduction of neoadjuvant therapy is to prevent disease progression and reduce              
wait-list dropouts. The choice of therapy depends on the degree of tumor invasion but all options                
involve a type of minimally invasive image-guided technique. 
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 Aside from preventing disease progression, another implementation of neo-adjuvant therapy is based            
on the principle of downstaging: using local ablation or chemoembolization in HCC in order to fulfill                
the Milan Criteria for liver transplantation. Despite a few small promising prospective studies, there is               
an overall lack of large, well-designed research in this field ​(19,20)​. The EASL-EORTC panel does,               
however, recommend adopting downstaging interventions in specific cases, such as in HCC patients             
who have progressed beyond the Milan Criteria while awaiting liver transplantation ​(6)​. 
The fourth and final treatment modality of HCC as outlined in the BCLC staging system is a number                  
of local, image-guided, minimally invasive therapies. These techniques can be divided into            
tumor-ablative and image-guided, catheter based treatment modalities. The former technique uses           
either thermal or chemical destruction. Thermal ablation includes procedures such as radiofrequency,            
cryotherapy, microwave, laser, or high-intensity focused ultrasound ablation. Chemical ablation          
involves percutaneous injection of ethanol into the tumor. As indicated by the BCLC staging,              
tumor-ablative therapies are modalities mainly aimed at early-stage HCC, whereas image-guided           
catheter based intervention delivering embolic, chemoembolic, or radio-embolic agents intra-arterially          
are primarily indicated for intermediate-stage HCC. 
The introduction of minimally invasive, image-guided therapeutic modalities has revolutionized the           
treatment of HCC. This review will provide an overview of all employed procedures and evaluate               
their scientific evidence and clinical use. 
 
 
2.  Tumor-ablation techniques 
 
2.1 Chemical ablation 
 
Introduced in the 1980s, percutaneous ethanol injection (PEI) is one of the oldest and most established                
loco-regional therapies for HCC ​(21,22)​. Despite advances in thermal ablation techniques, PEI is still              
included in the recommended treatment modalities for early stage HCC (BCLC 0, A) and is not                
suitable for surgery ​(6)​.  
It is believed that injection of 95% ethanol into the primary tumor under US or CT guidance results in                   
immediate dehydration of the neoplastic cells and denaturation of cellular proteins, ultimately            
culminating in coagulative necrosis. Additionally, local vascular thrombosis, the result of either            
endothelial damage due to the ethanol itself or due to the surrounding necrotic cells, may contribute to                 
tumor destruction through ischemic tissue necrosis ​(23,24)​. Initial success rate of PEI for single              
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 nodule HCC approaches 100% for nodules <2 cm, followed by 70% and 50% in nodules <3 cm and                  
<5 cm, respectively ​(25)​. However, randomised control trials have shown PEI to require more              
sessions in order to achieve full tumor necrosis, with subsequent longer hospitalisation when             
compared to other local ablative therapies like radiofrequency ablation (RFA),​(26,27)​. Overall 3, 5             
and 7-year survival rates for HCC <3 cm are comparable across several studies, measuring 78%, 54%                
and 28%, respectively ​(28–30)​. The therapeutic effect of PEI has been shown to be largely dependant                
on tumor size, with frequency of microscopic portal invasion being significantly higher in HCC size               
16-20mm (40%) compared to HCC size 11-15mm (25%) ​(31)​. ​As indicated in the previous discussion               
on the introduction of the BCLC scoring system, another major contributor to OS in HCC patients                
treated with PEI is liver function. Shiina et al. reported a significant decrease in survival rates with                 
increased level of liver dysfunction (Child-Pugh class A-C). 3 and 5-year survival rates declined from               
77% and 58% in Child-Pugh class A, to 54% and 36% in class B and 38% and 19% in Child-Pugh                    
class C ​(32)​. ​However, the major pitfall for PEI in treatment of HCC is comparatively high recurrence                 
rates. While there is no significant difference in ​de novo HCC development and extrahepatic              
metastasis incidence when comparing PEI and RFA, local recurrence rates are significantly higher in              
PEI. Several studies have reported cumulative local recurrence rates at 2 and 3 years between 16-23%                
and 34-45% ​(27,33)​. Shuichiro et al. reported an 88% smaller risk of local tumor progression in RFA                 
compared to PEI ​(26)​. Nonetheless, with its low treatment costs and its comparable success rate for                
small HCC nodules <2 cm, PEI remains part of the standard care for patients with BCLC 0-A tumors                  
not suitable for surgical resection ​(6)​. Furthermore, studies focusing on the recent introduction of              
multi-pronged needles with three retractable prongs, reporting successful eradication of HCC up to 5              
cm in only 1-2 treatment sessions, demonstrate that PEI may still play an important role in HCC                 
therapy in the future ​(34)​.  
 
2.2 Radiofrequency ablation 
 
nducing coagulative necrosis with the introduction of a local electric current, RFA is the most               
widely-used thermal ablative technique to date. During the procedure, a small electrode is introduced              
into the primary tumor percutaneously, laparoscopically, or via laparotomy. While running a            
high-frequency alternating current through the electrode, ionic movement in the adjacent tissue results             
in frictional heating and irreversible cellular injury at temperatures around 50° C. Following the              
procedure, the damaged tissue undergoes apoptosis resulting in the coagulative necrosis of the tumor              
cells ​(35)​. The efficiency of the treatment is ultimately limited by an increasing circuit impedance, as                
a result of tissue dehydration through water vaporization. A number of additional modalities have              
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 been introduced in order to slow development of circuit impedance. These modalities include larger              
surface area of the electrode through multi-tined electrodes, pulsating power, and injections of saline              
(36)​. A major limiting factor to RFA is the “heat sink” effect, in which thermal ablative effects are                  
dissipated due to local blood flow in vessels of at least 3 mm in diameter, thereby limiting its efficacy                   
particularly near the liver hilum ​(37)​. RFA has proven effective in the treatment of small HCC tumors                 
<3 cm in very early-stage and early stage disease (BCLC 0-A) and is recommended as the main                 
ablative therapy in  tumors <5 cm ​(6)​.  
Despite recommendations outlined by the BCLC scoring system of prioritising surgical resection over             
RFA, recent studies have shown comparable results with regard to OS. In a randomized controlled               
trial, Lu et al. concluded 3-year survival outcome of RFA to be equivalent to surgical resection ​(38)​.                 
Furthermore, Feng et al. reported no statistical difference in overall and recurrence free survival when               
comparing RFA and surgical resection in patients with hepatocellular nodules of <4 cm ​(39)​. This               
conclusion was further supported by a meta-analysis of 4 randomised controlled trials comparing RFA              
with surgical resection between 1990 and 2010, describing no statistically significant difference in OS              
between the two treatment modalities ​(40)​. Finally, Livraghi et al. concluded in their retrospective              
cohort study that RFA can be a treatment of choice for patients with tumors ≤2 cm, despite primarily                  
being surgical candidates ​(41)​.  
One of the inherent benefits of ablative treatment modalities like RFA is the minimally invasive               
nature of the procedure and the associated low incidence of complications. Based on their extensive               
literature review encompassing publications from January 1990 to December 2001, Mulier et al.             
reported of a mortality rate of 0.5% and an 8.9% incidence of major complications, concluding that                
the morbidity and mortality rates associated with RFA are higher than previously assumed ​(42)​.              
However, more recent research by Livraghi et al., Giorgio et al. and Chen et al. report rates as low as                    
0.9% to 5.2% for major complications, as well as mortality rates of 0.3% ​(43–45)​. The most common                 
major complications include peritoneal hemorrhage, intra-abdominal infections ranging from hepatic          
abscess to sepsis, biliary tract damage, hepatic decompensation and neoplastic seeding ​(46)​.            
Needle-track seeding in particular has gathered much attention. In 2001, Llovet et al. demonstrated              
biopsy-proven needle-track seeding in 12.5% of their 32 patients ​(47)​. In line with their observations,               
a more recent study by Snoeren et al. confirmed viable tumor cells adherent to needle applicators                
after ablation in 26.7% of patients, concluding that a major independent risk factor is failure to                
perform track ablation ​(48)​. However, several researchers found the incidence of needle-track seeding             
to be much lower. Jaskolka et al. reported an incidence rate of 4%, Imamura et al. of 3.2% and                   
Livraghi as low as 0.9% ​(49,50)​. Specific risk factors reported included poor degree of differentiation               
of the primary tumor, needle biopsy performed previous to RFA intervention, subcapsular location, as              
well as multiple sessions and lesions requiring multiple electrodes ​(49)​. 
6 
  
2.3 Cryoablation 
 
Unlike the process of heating applied in RFA, Cryoablation utilizes the process of freezing and               
thawing by introducing an applicator percutaneously into the primary tumor. Freezing the            
applicator’s surrounding tissue very quickly down to a range from -40°C to -60°C leads to               
intracellular ice crystal formation. This formation results in damage to cellular membranes and             
organelles, culminating in cell destruction. Any remaining viable cell after the first freezing will take               
up water from the surrounding hypotonic interstitium during thawing, which will in turn yield more               
crystal formation in subsequent freezing intervals ​(51)​. In addition, local microvascular collapse as a              
result of endothelial damage from ice crystals further contributes to tissue destruction through local              
ischemia ​(52)​. Despite research demonstrating that healthy liver cells can only resist temperatures of              
-15°C to -20°C, tumor cells have been shown to be more temperature-variable and resistant to               
freezing injury, which explains the use of much lower temperatures during Cryoablation ​(53)​.  
In the past, Cryoablation for HCC was regarded critically due to severe complications involving              
“Cryoshock”. Seifert et al. reported Cryoshock complications in 1% of performed hepatic cryotherapy             
patients. Furthermore, they associated Cryoshock with a high risk of death, contributing to 18.2% of               
perioperative mortality ​(54)​. In a more recent randomised controlled multicenter study, however,            
Wang et al. reported of incidents of Cryoshock and no treatment-related mortality ​(55)​. The authors               
further compared the efficacy of Cryoablation with RFA in patients with HCC ≤2 nodules measuring               
≤4 cm each with underlying cirrhosis in Child-Pugh class A or B. OS rates at 1, 3 and 5 years were                     
comparable between the two treatment modalities, being 97%, 67% and 40% for RFA and 97%, 66%                
and 38% for Cryotherapy, respectively. Additionally, the complication rate was similar at 3.9% for              
RFA and 3.3% for Cryotherapy. Similar 1 and 3-year survival rates have been reported by Shimizu et                 
al. in 2009 (93.8% for 1-year and 79.3% for 3-year OS) ​(56)​. Contrary to the comparable                
complication rates reported by Wang et al., a meta-analysis conducted by Wu et al. points to a                 
significantly higher risk of complications with cryotherapy, particularly with regards to           
treatment-related bleeding, thrombocytopenia, and renal impairment. Their explanation for the          
increased incidence of bleeding is the lack of electrocautery of the needle tract during cryoablation               
(57)​.  
 
7 
  
2.4 Microwave ablation 
 
Microwave ablation (MWA) achieves local tissue destruction in a similar fashion to RFA. After              
introduction of a MWA probe into the primary tumor under US guidance, an electromagnetic (EM)               
field emitted by the probe results in the oscillation of water molecules in the surrounding tissue.                
Depending on the effective conductivity of the specific tissue, a fraction of the EM field is absorbed                 
and converted to heat. Tissue destruction as a result of heating is comparable to the processes occuring                 
in RFA. One seemingly important difference to RFA, however, is that EM energy propagation is not                
negatively influenced by increasing impedance of the charred tissue surrounding the probe, allowing             
for larger ablative zones without the need of additional modalities like saline injections. In addition,               
multiple simultaneously-introduced probes in MWA, when positioned correctly, allow for increased           
tissue heating in overlapping EM field areas. By comparison, multi-probe application in RFA only              
allows one probe to be active at a time. In summary, MWA allows for the faster heating of larger                   
ablation zones as compared to RFA ​(58,59)​.  
Seki et al. observed significantly higher 5-year survival rates in patients with moderately to              
poorly-differentiated HCC ≤2 cm when treated with MWA as compared to with PEI. This observation               
was shared in the group with well-differentiated HCC ​(60)​. Considerably more research has been done               
with the aim of comparing MWA to RFA, resulting in no significant differences with regard to OS. In                  
2005, Lu et al. reported 1, 2, 3, and 4-year cumulative survival rates for MWA of 81.6%, 61.2%,                  
50.5% and 36.8%, respectively. They concluded that both modalities are equally valuable with regard              
to local tumor control and complication rate ​(61)​. Conversely, Ohmoto et al. concluded that RFA is                
superior to MWA due to the need for fewer treatment sessions, lower local recurrences, and higher                
cumulative survival rates. They also reported a higher incidence of minor complications such as pain               
and fever and pointed out several serious complications including bile duct injuries, intraperitoneal             
bleeding, and hepatic infarctions that were associated with MWA treatment ​(62)​. However, in line              
with results compiled by Lu et al., more recent research by Ding et al. and Abdelaziz et al., show that                    
RFA and MWA are of similar clinical value for the treatment of HCC ​(63,64)​.  
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2.5 Laser ablation 
 
Laser ablation (LA) as a treatment modality for the ablation of tumors was first introduced by Bown                 
et al. in 1983 ​(65)​. In current practice, a neodymium-doped yttrium aluminum garnet laser (Nd-YAG)               
with a wavelength of 1064 nm or a diode laser is introduced under combined US and CT or MR                   
guidance. Light in the near infrared spectrum emitted from the fiber tip permeates into the               
surrounding tissue resulting in partial reflection and absorption. Absorbed energy is converted into             
heat, ultimately resulting in coagulative necrosis, comparable to the process described in RFA. With a               
single tip application, a maximum spherical lesion of 12-16 mm in diameter can be achieved. In order                 
to achieve larger ablation zones of >5 cm, multiple fibres have to be placed at 2 cm distance to each                    
other ​(66–68)​. According to data collected by Gough-Palmer et al., the ideal criteria for LA in HCC                 
have been described as <3 cm in diameter, deep in the liver parenchyma, while severe liver disease                 
(Child Pugh Class C) and coagulopathy have been considered relative contraindications ​(69)​.            
Meanwhile, Pacella et al. concluded in their retrospective analysis that tumors should not exceed 2               
cm in size with normal liver function as represented by serum albumin levels >3.5 g/dl. They further                 
describe achieving complete ablation in 79.6%, with the highest rates in nodules ≤2 cm (85.1%). 3                
and 5-year cumulative survival rates were recorded at 61% and 34%, respectively. Lastly, via Cox               
analysis, Pacella et al. identified serum albumin >3.5 g/dl, complete tumor ablation and age <73 years                
as independent predictors of survival. ​(70) Interestingly, according to a retrospective study conducted             
by Giampiero et al. analyzing 182 HCC nodules ≤4 cm in 164 patients, tumor location does not affect                  
safety, effectiveness, or local tumor progression. After dividing patients into high-risk and            
standard-risk groups based on the location of the nodule, the researchers reported no significant              
difference between the two groups in respect to initial ablation rate, major complication rate,              
cumulative incidence of local tumor progression or local tumor-free survival ​(71)​. Comparing LA             
and RFA, a recent randomised controlled trial conducted by Di Costanzo et al. points to no significant                 
difference between the two treatment modalities in respect to proportion of complete tumor ablation,              
time to local tumor progression, and OS. In their conclusion, the researchers suggest that LA be                
considered as an alternative to thermal ablation in small nodule HCC ​(72)​. Lastly, with the application                
of multifibre LA under a newly designed US needle guidance system, researchers have been able to                
achieve 91.7% complete ablation of nodules ≤5 cm ​(73)​.  
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 2.6 High-intensity focused ultrasound 
 
Despite the principle behind being rather old, High-intensity focused ultrasound (HIFU) is one of the               
latest modalities with regards to treatment of HCC. With the use of an extracorporeal transducer, this                
treatment option is, in theory, completely non-invasive. At a frequency of 0.8-3.5 MHz, US waves can                
be bundled at a particular distance from the transducer with a local tissue temperature increase beyond                
60°C, ultimately resulting in coagulative necrosis in the tumor focus ​(74)​. In 2004, Wu et al.                
conducted a non randomised clinical trial involving 51 patients with an average tumor size of 8.14                
cm. OS was reportedly at 86.1%, 61.5% and 35.3% for 6, 12, and 18 months, respectively. In                 
conclusion Wu et al. describe HIFU as an effective, safe and feasible treatment modality for HCC                
(75)​. However, prior to the use of HIFU, half the trial population had been treated with transarterial                 
chemoembolization (TACE) and rib resections had been performed on 14 patients. The purpose and              
effect of rib resection was the subject of another study conducted by Zhu et al. In their study, 16                   
patients with HCC at a mean diameter of 7.0 cm were treated with HIFU. All patients previously                 
underwent rib resection in order to minimize US reflection. According to Zhu et al., US reflection not                 
only reduces efficacy of HIFU but also increases the chance of complications of soft tissue and skin                 
burns. Survival rates at 1, 2, 3, 4, and 5 years were reported as 100%, 83.3%, 69.4%, 55.6% and                   
55.6%, respectively ​(76)​. Nonetheless, prior rib resection in order to create an improved acoustic              
pathway for US beams, while effective, renders the feasibility and non-invasive nature of HIFU into               
question. Experimental measurements introducing segmented transducers for HIFU, however,         
promise to avoid the need for rib resection in the future ​(77)​. More recent research has been done with                   
a focus on using HIFU as a bridging therapy for HCC prior to liver transplantation. In 2013, Cheung                  
et al. compared response rates and dropout rates among prospective transplant recipients treated with              
transarterial chemoembolization (TACE) and HIFU. Of the limited number of patients receiving            
HIFU, 90% had complete response as compared to 3% in the TACE group. In their conclusion, the                 
researchers describe HIFU as safe and effective and propose a possible reduction in dropout rates               
(78)​. In a pilot study, Chok et al. compared TACE, HIFU and no bridging therapy. Their results                 
pointed to no significant difference between patients who had received TACE or HIFU, however both               
were superior to no bridging therapy at all. Still, with the inclusion of HIFU as an alternative to TACE                   
for bridging to liver transplantation, adoption of pre-transplant therapy has increased from 39.2% to              
80.4%, thanks in part to the eligibility of HIFU in severe liver disease (Child-Pugh C) and in patients                  
contraindicated to receive TACE ​(79)​. 
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 3. Intra-arterial interventions 
 
Intra-arterial interventions for HCC, both primary and metastatic were first introduced in the late              
1970s. Allison et al. reported symptomatic relief after treating patients with multiple hepatic carcinoid              
metastases by embolising the hepatic artery with an absorbable gelatin sponge ​(80)​. However, the              
particular physiological feature of HCC the therapy utilizes is based on was first described back in                
1954. After injecting a solution containing ink into the portal vein and into the hepatic artery of                 
several animal test subjects as well as postmortem human livers, researchers noticed a significant              
difference in patterns of pigment distribution throughout the livers. Portal vein injections resulted in              
colour uptake throughout the liver parenchyma with tumors remaining largely colourless. In contrast,             
tumor and adjacent tissue colourisation occured after injecting pigment solution into the hepatic             
artery. Breedis et al. therefore concluded that blood supply to all malignant tumors in the liver were                 
almost exclusively arterial ​(81)​.  
During intra-arterial interventions for HCC, a catheter is introduced into the hepatic artery or one of                
its lobar or segmental subsidiaries. Through this catheter, an embolic agent either alone or in               
combination with a highly concentrated dose of a chemotherapeutic- or radiotherapeutic agent is             
delivered into close proximity of the tumor. There are several types of intra-arterial interventions              
based on the combination of agents used, including transarterial chemoembolization, transarterial           
bland embolization (TAE) and transarterial radioembolization (TARE) ​(82)​. 
 
3.1 Transarterial chemoembolization 
 
TACE is regarded as the gold standard for patients meeting BCLC B staging criteria. These               
intermediate-stage HCC include inoperable multinodular asymptomatic tumors with no signs of           
vascular invasion or extrahepatic spread and adequate liver function (Child Pugh class A, B) ​(6)​.               
During TACE, a chemotherapeutic agent is mixed with an oil-based radiopaque contrast agent- most              
commonly lipiodol- and delivered trans-arterially to the tumor site. Following the administration of             
the chemotherapeutic-lipiodol emulsion, an embolic agent is infused. The resulting arterial occlusion            
serves twofold by reducing blood supply, thereby inducing ischemic tumor damage, and by reducing              
washout of the chemotherapeutic agent and consequently prolonging cytotoxic tumor exposure ​(83)​.            
Globally, the most commonly used chemotherapeutic agent is Doxorubicin. However, cisplatin,           
epirubicin, mitomycin and other cisplatin derivatives have been used, too. In general, no consensus              
has been achieved on which chemotherapeutic agent is superior for application in TACE. Several              
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 studies have been conducted comparing cisplatin-based emulsions with emulsions containing          
epirubicin or miriplatin, with no obvious answer as to which is the optimal chemotherapeutic agent               
(84)​.  
The essential studies establishing its importance in the treatment of HCC were conducted in the early                
2000s. In 2002, Llovet et al. published their results on survival probabilities after treatment with               
arterial embolization, chemoembolization and conservative treatment. Researchers reported OS at 1,           
2 and 3 years. While results of embolization were higher than the conservative group (75%, 50% and                 
29% OS compared to 63%, 27% and 17%, respectively), TACE proved to be significantly superior               
over conservative treatment (82%, 63% and 29% OS at p=0.009). Of note, Llovet et al. only included                 
patients with adequate liver function as represented by Child-Pugh class A and B ​(85)​. In the same                 
year, Lo et al. reported similar OS rates at 1, 2 and 3 years when comparing TACE with conservative                   
treatment (57%, 31% and 26% compared to 32%, 11% and 3%, respectively). In their conclusion, the                
researchers point out a major limiting factor for the application of TACE is the presence of unilobar                 
portal vein obstruction, estimating a threefold increased risk of death ​(86)​. In 2011, a cochrane               
meta-analysis called into the question the benefits of chemoembolization. According to the authors,             
research into TACE lacked evidence of improving survival in patients with unresectable HCC ​(87)​.              
However, this article has been criticized by experts over their decision of excluding trials that showed                
benefit in survival after TACE as well as including trials focusing on TAE rather than TACE ​(88,89) .                  
Lastly, a recent systematic review aimed at identifying efficacy and safety of TACE was conducted by                
Lencioni et al. In their data collection, including 10,108 patients treated in 101 studies, researchers               
reported a longer median survival and higher 3-year OS when comparing studies conducted until 2002               
and after ​(90)​. 
As described by the treatment criteria issued by EASL-EORTC, degree of liver dysfunction plays a               
critical part in patient selection. More specifically, absolute contraindications for TACE include            
decompensated liver cirrhosis (Child-Pugh B ≥8), extensive tumor replacement of both liver lobes as              
well as severely reduced portal vein flow ​(6,91)​.  
Novel approaches in order to increase exposure time of cytotoxic agents to tumor cells while               
minimizing systemic side effects have been made. Drug-eluting beads (DEB) consist of nonresorbable             
polyviniyl alcohol (PVA) polymeric microspheres or acrylic copolymer microspheres that are capable            
of reversibly binding to polar molecules the likes of doxorubicin ​(92)​. This approach of drug delivery                
allows for fixed and gradual release of chemotherapeutic agents with significantly lower plasma             
concentrations when compared to conventional TACE (cTACE) ​(83,93,94)​. Furthermore, compared          
to cTACE, DEB-TACE has proven to provide improved tolerability with significant reduction in             
serious liver toxicity ​(95,96)​. With regard to local tumor control and OS, research has shown no                
significant benefit of DEB-TACE over cTACE. Recchia et al. reported statistically insignificant            
12 
 results of median OS of 11.4 and 18.4 months for cTACE and DEB-TACE, respectively ​(97)​. In                
2014, Golfieri et al. released their results of 1- and 2-year survival rates, illustrating similar               
insignificant differences between the two procedures with regards to survival (86.2% and 56.8% after              
DEB-TACE and 83.5% and 55.4% after cTACE) ​(98)​.  
 
3.2 Transarterial bland  embolization 
 
TAE or transcatheter arterial embolization follows the same principle previously described under            
TACE: blockage of hepatic arterial flow to the tumor with a vascular occlusion agent. Agents               
commonly used include Gelfoam, polyvinyl alcohol or calibrated microspheres ​(82)​. Despite TACE            
largely replacing TAE as the prefered treatment modality for BCLC B HCC tumors, evidence of any                
superiority of TACE in terms of OS or recurrence-free survival is lacking. In a 2014 retrospective                
case-controlled study, Kluger et al. compared percentage of achieved complete necrosis, 3-year OS             
and 3-year recurrence-free survival between 25 and 50 patients treated with TAE and TACE prior to                
liver transplantation, respectively. At 1- and 3-year OS rates of 96% and 78% for TAE versus 94%                 
and 74% for TACE, respectively, no significant difference between the two modalities could be              
established. The same could be observed in recurrence -free survival at 1 and 3 years, with neither                 
therapy proving to be significantly superior to the other (91% and 72% for TAE, 92% and 68% for                  
TACE, respectively) ​(99)​. In another recent small-scale trial, researchers compared embolization           
using microspheres alone with microspheres loaded with doxorubicin 150mg. Brown et al. confirmed             
no significant difference between the two treatment modalities with regard to progression-free            
survival (6.2 months versus 2.8 months) and OS (19.6 months versus 20.8 months) ​(100)​. In fact, in a                  
2007 published meta-analysis, Marelli et al. question the efficacy of any chemotherapeutic agent             
utilized in TACE, accounting its therapeutic effect on the embolization aspect of the therapeutic              
intervention ​(101)​. However, with some research stipulating that embolization could potentially result            
in hypoxia-induced angiogenesis and consequently tumor growth promotion, combining TAE with           
antiangiogenic agents rather than chemotherapeutic agents could prove beneficial ​(102,103)​. The first            
early studies combining TAE with antiangiogenic agents in the treatment of rat liver tumors show               
promising results ​(104,105)​.  
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3.3 Transarterial radioembolization  
 
Delivery of high dose radiation through intraarterial injection of microspheres loaded with a             
radioactive agent is the basis of TARE. Radioactive agents typically used include Yttrium-90 or              
lipiodol-labeled iodine-131 ​(106)​. Therapeutic effect is based on both embolic effects exerted by the              
microspheres as well as brachytherapy. However, compared to TAE or TACE, due to the smaller               
diameter of the delivering microspheres, ischemic effects from embolization contribute far less to the              
overall therapeutic effect ​(107)​. Moreover, the lack of macro-embolization increases safety potential            
for patients with portal vein thrombosis- a clear contraindication for both TACE and TAE ​(106,108)​.  
Research surrounding TARE focuses either on treatment of intermediate HCC (BCLC B) with             
comparison to TACE or as an alternative for downstaging treatment modalities prior to resection or               
transplantation. Several studies comparing TACE and TARE with focus on tumor response and OS              
have found no significant difference between the two treatment modalities ​(109–112)​. Salem et al.              
pointed out, despite median survival times not being significantly different, time-to-progression was            
longer after TARE compared to TACE (13.3 months compared to 8.4 months) ​(111)​. Furthermore,              
Fouly et al. reported a significantly lower number of treatment sessions, associated total             
hospitalization time and incidence of adverse events after TARE treatment ​(112)​. Another aspect in              
focus of research is the possibility of utilizing TARE as a mean of downstaging or bridging HCC until                  
curative treatment is possible or transplantation is available. In 2009, Lewandowski et al. reported              
significantly longer event-free survival after TARE compared to TACE (17.7 months compared to 7.1              
months, respectively). Additionally, successful downstaging to United Network for Organ Sharing           
(UNOS) T2 transplant criteria was achieved in 58% of TARE patients opposed to 31% of TACE                
patients ​(113)​. In another small retrospective study, Iñarrairaegui et al. reported successful            
downstaging in 6 of 21 patients with UNOS T3 stage, with varying median OS between patients who                 
were treated radically after successful downstaging compared to patients who received palliative            
treatment only. The researchers conclude that successful downstaging with TARE followed by radical             
therapy would provide long-term survival for patients with UNOS T3 stage ​(114)​. 
 
 
14 
  
4. Combination therapy 
 
Despite not being explicitly defined in the EASL-EORTC guidelines for treatment of HCC, some              
studies have focused on improving the efficiency of local therapies by combining them with other               
local or systemic therapies. One particular combination, local ablative therapy in conjunction with             
transarterial embolization techniques, has been the subject of a number of studies. As mentioned              
previously, one factor limiting the extent and efficacy of RFA is the process of “heat sink”, which                 
results from peri-tumoral vascularization and consequent loss of temperature into the circulation ​(37)​.             
Prior TACE should, in theory, reduce the effect of “heat sink” by occlusion of the vessels surrounding                 
and feeding the tumor. Recent studies have shown promising results ​(115–117)​. In 2012, Peng et al.                
compared sequential TACE and RFA with RFA alone with regards to OS, recurrence-free survival in               
139 patients with recurrent HCC ≤5 cm. The researchers reported better OS and recurrence-free              
survival in tumors >3 cm, concluding higher efficacy for sequential TACE-RF ablation compared to              
RFA alone for this subpopulation ​(117)​. Moreover, in a recent meta-analysis involving 8 randomised              
controlled trials, Ni et al. compared 305 patients treated with RFA plus TACE as opposed to 292                 
patients treated with RFA alone. In their analysis, OS at 1, 2, and 3 years was significantly better after                   
combination therapy compared to monotherapy. Similar results were reported in recurrence-free           
survival at 3 and 5 years. Lastly, Ni et al. report significant improval of survival rates in tumors >3                   
cm only, which is in line with results reported by Peng et al. ​(117,118)​. 
Another approach to combination therapy that was subject to studies is the combination of systemic               
Sorafenib chemotherapy with intra-arterial intervention modalities, either TARE or TACE for           
advanced HCC. In 2014, Chow et al. published their findings of a Phase II trial involving TARE with                  
Sorafenib in 99 patients with BCLC B (38%) or BCLC C (62%) HCC. The researchers report a                 
median survival of 20.3 and 8.6 months for BCLC B and BCLC C, respectively, signifying potential                
efficacy of sequential TARE-Sorafenib therapy with manageable toxicity ​(119)​. The latter observation            
is further confirmed by a 2015 European multicentre trial comparing safety and toxicity of TARE plus                
Sorafenib versus Sorafenib alone. Ricke et al. point out similar tolerability between the two study               
arms ​(120)​. Lastly, a recent small trial involving 19 patients with BCLC B or C HCC who were                  
treated sequentially with TARE and Sorafenib reported an OS of 19.52 months and progression-free              
survival of 6.63 months ​(121)​. Combination of TACE with Sorafenib has as well been subject to                
multiple studies. Qu et al. compared this combination of therapy in 45 patients with BCLC B (36%)                 
and BCLC C (64%) with a control group receiving TACE only. Alongside significantly less frequent               
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 TACE interventions for symptomatic relief, the researchers demonstrated a significant difference in            
median OS between the combination group and the control group (27 months median OS versus 17                
months, respectively), irrespective of the presence of PVT ​(122)​. In 2013, Choi et al. compared TACE                
with Sorafenib to Sorafenib only in a retrospective analysis in a total of 355 patients with advanced                 
HCC (BCLC C). With a median time to progression of 2.7 months and 2.1 months (P= 0.011) and a                   
median OS of 9.1 months and 6.7 months (P= 0.21) for combination therapy and monotherapy,               
respectively, they demonstrated the combination of TACE with Sorafenib is superior to Sorafenib             
only with regards to time to progression ​(123)​. 
 
 
5. Conclusion 
 
Image-guided, minimally invasive therapies play a key role in the management of HCC. On one hand,                
there are the tumor ablative techniques, which offer potential long-term survival for patients with              
early-stage HCC who are unable to undergo surgical intervention. Aside from RFA, other ablative              
therapies have proven their worth in studies. The choice of treatment should be based on the                
individual characteristics of the tumor, the location of the tumor, the residual liver function, as well as                 
the patient’s overall well-being. Lastly, with the introduction of HIFU, a new form of intervention has                
emerged that provides a completely non-invasive treatment modality for HCC that may further             
revolutionize this field of interventional radiology. 
On the other hand, intra-arterial intervention techniques have solidified their key role in the treatment               
of intermediate HCC, a stage in which no other treatment modality has shown a comparably               
significant benefit. With novel approaches such as microspheres labeled with radioactive components            
or filled with chemotherapeutic agents, precision of radiotherapy and chemotherapy in the field of              
interventional radiology has reached new levels. Considering the dismal survival rates for late-stage             
HCC, further studies will need to evaluate whether combining minimally-invasive therapies with            
systemic therapies can indeed yield better results than our current treatment options.  
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